2021 Growth opportunities on Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

2021 Growth opportunities on Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets

Description:

$39.0 billion market for Type 2 Diabetes Mellitus Therapeutics in Major Developed industry to 2021. Browse the following link, for more information @ – PowerPoint PPT presentation

Number of Views:27

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: 2021 Growth opportunities on Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets


1
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021- Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth
The Global T2DM market is expected to increase in
value at a CAGR of 7.5 from 23.5 billion to
39.0 billion.
Click Here To Check Complete Report
2
Summary of the Report Type 2 Diabetes Mellitus
(T2DM) is a metabolic disease characterized by
chronic hyperglycemia (high blood glucose
levels). Global prevalence has risen rapidly in
the past several decades, particularly in line
with obesity. This has been attributed to a range
of factors, including economic development,
increasing urbanization, aging populations, and
changes in lifestyle patterns such as reduced
levels of physical activity and consumption of
higher-calorie diets. This has led to strong
commercial interest in the development of T2DM
therapeutics. The current market is large and
diverse, comprising several drug classes,
including generic and branded drugs. Owing to the
range of therapeutic options available, the
treatment algorithm is complex. However, current
treatment regimens are often associated with
limited long-term efficacy, complex and
inconvenient dosing regimens, and undesirable
side effects such as weight gain and hypoglycemia
(low blood glucose levels).
3
Scope of the Report
  • Metformin monotherapy will remain the first-line
    pharmacotherapy for T2DM.
  • The emergence of several new drug classes over
    the past decade, namely the Glucagon-Like
    Peptide-1 (GLP-1) receptor agonists, Dipeptidyl
    Peptidase 4 (DPP-4) inhibitors, and
    SodiumGlucose Cotransporter 2 (SGLT-2)
    inhibitors, has led to considerable market
    growth.
  • How will the continued uptake of newer drug
    classes impact established drug classes such as
    the sulfonylureas and thiazolidinediones?
  • Leading insulin therapy Lantus (insulin glargine)
    recently lost patent protection in most major
    markets.
  • Will recently approved insulin therapies such as
    Tresiba (insulin degludec) and Toujeo (insulin
    glargine) be able to capture a significant
    portion of Lantus market share?
  • Over the 20142021 forecast period, the global
    T2DM market is expected to increase in value at a
    CAGR of 7.5 from 23.5 billion to 39.0 billion.
  • Which factors will drive market growth most
    significantly?
  • Strategic consolidation activity in T2DM is
    considerable, with US-based companies being key
    players.
  • Do T2DM products tend to attract high levels of
    investment?

Download Sample Brochure
4
Reasons to Buy
  • Understand the clinical context of the T2DM
    indication and the global burden of the disease
    by considering epidemiology, symptoms, etiology,
    pathophysiology, co-morbidities and
    complications, disease classification, disease
    prognosis, and treatment options
  • Appreciate the current T2DM marketed products
    landscape, including the dominant therapeutic
    strategies, products, and companies, and
    recognize gaps within the market and areas of
    unmet need
  • Identify key pipeline trends in molecule type and
    molecular target
  • Recognize the late-stage pipeline molecules that
    have demonstrated strong therapeutic potential in
    T2DM by examining clinical trial data and
    multi-scenario product forecast projections
  • Consider market opportunities and potential risks
    by examining trends in T2DM clinical trial size,
    duration, and failure rate by phase of
    development, molecule type, and molecular target
  • Discern variances in treatment usage patterns,
    annual therapy costs, and market growth
    projections for the US, Canada, the UK, France,
    Germany, Italy, Spain, and Japan
  • Discover how strategic consolidations have shaped
    the current T2DM pipeline and marketed products
    landscapes

Make an Inquiry Before Buying
5
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021- Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the global Type 2 Diabetes Mellitus Therapeutics
in Major Developed Markets and future
opportunities are provided in the report.
Click here to order a copy of Type 2 Diabetes
Mellitus Therapeutics Markets to 2021 Report
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
About PowerShow.com